期刊
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
卷 129, 期 8, 页码 456-462出版社
SPRINGER
DOI: 10.1007/s00432-003-0452-8
关键词
EGF-R; non-viral gene delivery system; histone
类别
Purpose. To construct an EGF receptor (EGF-R)-mediated histone H1(0)-based gene delivery system for gene therapy.Methods. A recombinant DNA containing histone H1(0), EGF-R ligand, and endosomalytic domains was constructed in a prokaryotic vector and expressed in E. coli. Expression of the beta-galactosidase (beta-gal) gene in the tumor cells and tissues was observed after transduction of the beta-gal gene packaged by purified fusion proteins in vitro and in vivo. Results. As an extension of the research on previously reported chemically synthetic composite polypeptide gene delivery systems, this genetically engineered polypeptide has proved to be capable of targeting the beta-galactosidase (beta-gal) gene into EGF-R-positive cancer cells both in vitro and in vivo. We also studied the time course of beta-gal gene expression in tumor tissues delivered in vivo by this polypeptide vector. At 24 h after administration, expression of the beta-galactosidase gene in tumor reached peak levels. The dosage optimization of administered polyplex was also investigated. The optimal dose of polyplex per mouse was 1 mug DNA packaged by 3 mug of composite polypeptide. Conclusions. The genetically engineered polypeptide based on histone H1(0) is a promising gene delivery system targeting EGF-R.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据